Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Net Margin (2021 - 2025)

Aligos Therapeutics' Net Margin history spans 5 years, with the latest figure at 11763.91% for Q4 2025.

  • For Q4 2025, Net Margin fell 927451.0% year-over-year to 11763.91%; the TTM value through Dec 2025 reached 1106.72%, up 97434.0%, while the annual FY2025 figure was 1106.72%, 252692.0% up from the prior year.
  • Net Margin reached 11763.91% in Q4 2025 per ALGS's latest filing, down from 4256.01% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 13854.66% in Q1 2025 to a low of 16396.43% in Q1 2023.
  • Average Net Margin over 5 years is 2799.49%, with a median of 1786.9% recorded in 2021.
  • Peak YoY movement for Net Margin: plummeted -1501117bps in 2023, then skyrocketed 1887815bps in 2025.
  • A 5-year view of Net Margin shows it stood at 10276.29% in 2021, then soared by 98bps to 157.37% in 2022, then tumbled by -782bps to 1388.35% in 2023, then crashed by -79bps to 2489.39% in 2024, then plummeted by -373bps to 11763.91% in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Net Margin are 11763.91% (Q4 2025), 4256.01% (Q3 2025), and 1643.83% (Q2 2025).